ArticleFrontiers in pharmacology2023

Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials.

Junlong Zhuang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.